anticholinesterase drugs

anticholinesterase drugs 

Parasympathetic drugs that inhibit or inactivate the enzyme acetylcholinesterase, allowing prolonged activity of acetylcholine. They cause miosis and ciliary muscle contraction. There are two groups: reversible which are of short duration (up to 12 hours or so), such as neostigmine, physostigmine and edrophonium chloride, and irreversible which lasts for days or weeks, such as demecarium bromide and diisopropyl fluorophosphate (DFP). See acetylcholinesterase; miotics.
References in periodicals archive ?
Infusion rate can be precisely controlled with simple monitoring techniques such as TOF count, to allow adjustment of blockade according to surgeon's need combination of continuous infusion of Atracurium or Vecuronium, monitored by TOF count, use of anticholinesterase drugs, permits safe and successful recovery.
At present, cerebroselective anticholinesterase drugs such as donepezil, rivastigmine, and galantamine are mainstay therapy in AD.
Anticholinesterase drugs are the first-line approach for managing symptoms, (5) with pyridostigmine bromide (mestinon) the most commonly used.
Treatment of JMG was adopted from adult patients and includes anticholinesterase drugs, steroids, immunosuppressants, plasmapheresis, IVIG, and thymectomy.
Background: The antagonistic actions of anticholinesterase drugs on non-depolarizing muscle relaxants are theoretically related to the activity of acetylcholinesterase (AChE) in the neuromuscular junction (NMJ).
After surgery, patients were transferred to the intensive care unit for elective overnight ventilation; midazolam and fentanyl infusions were discontinued early morning of the following day, no anticholinesterase drugs were added, and patients received their normal myasthenic therapy via the nasogastric tube.
The two types of cholinesterases (ChE) are present in vertebrates; AChE and BChE exhibit an aryl acylamidase activity (AAA), which is effectively inhibited by cholinergic and serotonergic agents (ACh, specific anticholinesterase drugs and serotonin) [50, 51].
These variants are more likely to affect the duration of response when present with other factors that influence BChE activity, such as a qualitative BChE variant, pregnancy, and anticholinesterase drugs (9).
Conventional treatment involves the use of steroid immune system suppressers such as prednisone, and anticholinesterase drugs, usually pyrodostigmine.
A nondepolarising neuromuscular blocking agent is an alternative, however their disadvantages include long duration of action, less effectiveness for deep neuromuscular blocking and muscarinic side-effects of anticholinesterase drugs (3,4) when they are used for reversal.
Both trials included patients who had been stable on anticholinesterase drugs for at least 3 months prior to the study.
About 95% were taking, anticholinesterase drugs. Mild Alzheimer's was present in 130 patients at baseline, while the rest had moderate-stage disease.